In addition, our findings failed to support chemotherapy alone or single anti-HER2 regimens in combination with chemotherapy (i.e., TC, PC, LC) as optimal neoadjuvant therapies for the treatment of early-stage HER2+ve breast cancer due to a very low chance of achieving pCR and an associated increased risk of SAE. This evidence concerns the gene ERBB2 and breast carcinoma.